Compare CASH & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CASH | HCM |
|---|---|---|
| Founded | 1954 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 1996 | N/A |
| Metric | CASH | HCM |
|---|---|---|
| Price | $91.14 | $11.54 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 2 | 1 |
| Target Price | ★ $107.50 | $13.75 |
| AVG Volume (30 Days) | ★ 195.0K | 43.0K |
| Earning Date | 04-22-2026 | 03-05-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | ★ 18.88 | N/A |
| EPS | ★ 4.89 | N/A |
| Revenue | ★ $839,894,000.00 | N/A |
| Revenue This Year | $7.56 | $20.60 |
| Revenue Next Year | $6.02 | $15.62 |
| P/E Ratio | $18.56 | ★ $5.49 |
| Revenue Growth | ★ 11.29 | N/A |
| 52 Week Low | $65.93 | $9.77 |
| 52 Week High | $101.26 | $18.17 |
| Indicator | CASH | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 57.99 | 57.06 |
| Support Level | $86.45 | $10.83 |
| Resistance Level | $94.61 | $11.80 |
| Average True Range (ATR) | 2.49 | 0.23 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 82.42 | 88.89 |
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.